Galmed Pharmaceuticals Q3 EPS $(0.21) Beats $(0.29) Estimate

Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.29) by 27.59 percent. This is a 320 percent decrease over losses of $(0.05) per share

Benzinga · 11/06/2019 12:18

Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.29) by 27.59 percent. This is a 320 percent decrease over losses of $(0.05) per share from the same period last year.